Summary
Gilead Sciences, Inc. reported solid financial results for the third quarter and first nine months of 2025, demonstrating revenue growth and a significant turnaround in profitability compared to the prior year. Total revenues for the third quarter of 2025 increased by 3% year-over-year to $7.8 billion, driven by strong performance in the HIV and Liver Disease segments, alongside a notable surge in royalty, contract, and other revenues. For the first nine months, total revenues grew 2% to $21.5 billion. The company achieved substantial net income of $3.1 billion for the quarter and $6.3 billion for the nine-month period, a significant improvement from the net loss reported in the comparable periods of 2024. This profitability boost was largely attributed to the absence of substantial impairment charges seen in the prior year, coupled with increased royalty income and lower acquired R&D expenses. Diluted earnings per share also saw a strong recovery, reflecting these improved financial outcomes.
Financial Highlights
55 data points| Revenue | $7.77B |
| Cost of Revenue | $1.57B |
| Gross Profit | $6.20B |
| SG&A Expenses | $1.36B |
| Operating Expenses | $4.44B |
| Operating Income | $3.33B |
| Net Income | $3.05B |
| EPS (Basic) | $2.46 |
| EPS (Diluted) | $2.43 |
| Shares Outstanding (Basic) | 1.24B |
| Shares Outstanding (Diluted) | 1.25B |
Key Highlights
- 1Total revenues increased by 3% to $7.8 billion for Q3 2025 and by 2% to $21.5 billion for the first nine months of 2025.
- 2Net income attributable to Gilead was $3.1 billion for Q3 2025, a significant improvement from $1.3 billion in Q3 2024. For the first nine months, net income was $6.3 billion compared to a net loss of $1.3 billion in the prior year.
- 3HIV product sales grew 4% in Q3 and 6% year-to-date, primarily driven by Biktarvy and Descovy.
- 4Liver Disease product sales saw a robust 12% increase in Q3 and 3% year-to-date, boosted by Livdelzi and HBV products.
- 5Veklury sales experienced a substantial decline of 60% in Q3 and 52% year-to-date, reflecting decreased COVID-19 hospitalizations.
- 6Significant R&D impairments seen in 2024 did not recur in 2025, contributing to improved profitability.
- 7Gilead announced a settlement resolving Biktarvy patent litigation with generic manufacturers, extending exclusivity to at least April 2036 in the U.S.